ArticleEndocrine2023
Trends in incidence and mortality risk for acromegaly in Norway: a cohort study.
Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden.The Journal of clinical endocrinology and metabolism · 2026Article
- Changing understanding of acromegaly epidemiology and early mortality risk.The Journal of clinical endocrinology and metabolism · 2026Review
- Recent progress in the understanding of psychological complications of acromegaly: toward a longitudinal clinical phenotype.Pituitary · 2026Review
- Impact of sex on mortality in patients with pituitary adenomas.Pituitary · 2026Review
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Outcome of acromegalic patients undergoing endoscopic endonasal surgery: collaborative French and Italian cohort, a 25-year experience.Neurosurgical review · 2025Article
- Prevalence of Neoplasms in Patients with Acromegaly-A Single-Center Polish Study.Journal of clinical medicine · 2024Article
- The changing landscape of acromegaly - an epidemiological perspective.Reviews in endocrine & metabolic disorders · 2024Review
- An Overview of Cardiovascular Risk in Pituitary Disorders.Medicina (Kaunas, Lithuania) · 2024Review
- Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.Journal of endocrinological investigation · 2024Observational
- Changes in acromegaly comorbidities, treatment, and outcome over three decades: a nationwide cohort study.Frontiers in endocrinology · 2024Article
- High mortality risk among women with acromegaly still persists.Frontiers in endocrinology · 2024Observational
- Long-term control of acromegaly after pituitary surgery in South-Eastern Norway.Acta neurochirurgica · 2023Article
- Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent data have shown a decreasing overall mortality in acromegaly over the last decades. However, cancer incidence and cancer-related mortality still appear to be increased. Our aim was to obtain updated epidemiological data from Norway in a clinically well-defined cohort with complete register-based follow-up.
methodsPatients diagnosed with acromegaly from South-Eastern Norway between 1999-2019 (n = 262) and age and sex matched population controls (1:100) were included (n = 26,200). Mortality and cancer data were obtained from the Norwegian Cause of Death and Cancer Registry. Mortality and cancer incidence were compared by Kaplan-Meier analyses and Cox regression; we report hazard ratios (HRs) with 95% confidence intervals (95% CI).
resultsMedian age at diagnosis was 48.0 years (interquartile range (IQR): 37.6-58.0). Mean annual acromegaly incidence rate was 4.7 (95% CI 4.2-5.3) cases/10
conclusionIn this large cohort study, covering the period 1999-2019, patients were treated with individualized multimodal management. Mortality was not increased compared to the general population and comparable with recent registry studies from the Nordic countries and Europe. Overall cancer risk was slightly, but not significantly increased in the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.